298-46-4 | Carbamazepine

Chemical type

• Antiseizure medication (ASM) and potential P-gp substrate

^[1]

• Antiepileptic drug
• Pharmaceutical

^[2]

Key properties

• Enzyme-inducing ASM that may lower tariquidar plasma levels at low doses
• Brain entry potentially limited by P-gp overactivity

^[1]

• Long-established anticonvulsant and mood stabilizer
• Metabolized into an active metabolite (carbamazepine-10,11-epoxide)
• Can cause neurological adverse effects (drowsiness, dizziness, ataxia, dysarthria) even at therapeutic levels, especially in drug-naive individuals
• Half-life of 12-17 hours for the parent compound

^[2]

• Treatment of drug-resistant epilepsy (e.g., mesial temporal lobe epilepsy)
• Co-administered with P-gp inhibitors in studies

^[1]

• Treatment of epilepsy
• Management of bipolar disorder
• Relief of trigeminal neuralgia

^[2]

Classification by use

• Chemicals used as antiseizure medications
• Enzyme inducers in pharmacotherapy

^[1]

• Essential medicine

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] Tolerability of tariquidar – A third generation P-gp inhibitor as add-on medication to antiseizure medications in drug-resistant epilepsy, Seizure: European Journal of Epilepsy, Volume 119, July 2024, Pages 44-51
2. [Cite:2] Criminal use of carbamazepine: A case of drug-facilitated captivity in Lubumbashi, DR Congo, Forensic Science International: Reports, Volume 13, June 2026, 100441